Press Room

News / Mar 10, 2021

It's B Corp Month

We are proud to be a B Corporation.

B Corp Month | Hovione

This March is B Corp month – a whole month dedicated to celebrating businesses who are doing things differently and driving change and raising awareness in a globally coordinated social media effort to celebrate B Corps.

In 2017, we became a Certified B Corp. Being the first Chemical/ Pharmaceutical Company integrating an innovative community of companies that use the power of business to solve social and environmental problems.

Being a B Corporation means that to ensure our long‑term viability we will contribute positively to economic, environmental, and social sustainability.

B Corp Month | Hovione

As a Certified B CorporationTM we want to contribute to redefine success in business, meeting the highest standards of social and environmental performance, setting our Team Members for success and personal satisfaction, and aspiring to use the power of markets to solve social and environmental problems. Collectively, B Corps lead a growing global movement of people using business as a force for goodTM.

We are proud to be a B Corporation.

 

B Corp Month | Hovione

 

B Corp Month | Hovione

 

B Corp Month | Hovione

 

B Corp Month | Hovione

 

B Corp Month | Hovione

 

B Corp Month | Hovione

 

 

Learn more about Hovione being a B Corporation

 

 

B Corporation Certification logo | Hovione

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026